Bedside to bench and back again: How animal models are guiding the development of new immunotherapies for cancer

Steven E. Finkelstein, David M. Heimann, Christopher A. Klebanoff, Paul A. Antony, Luca Gattinoni, Christian S. Hinrichs, Leroy N. Hwang, Douglas C. Palmer, Paul J. Spiess, Deborah R. Surman, Claudia Wrzesiniski, Zhiya Yu, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticle

Abstract

Immunotherapy using adoptive cell transfer is a promising approach that can result in the regression of bulky, invasive cancer in some patients. However, currently available therapies remain less successful than desired. To study the mechanisms of action and possible improvements in cell-transfer therapies, we use a murine model system with analogous components to the treatment of patients. T cell receptor transgenic CD8+ T cells (pmel-1) specifically recognizing the melanocyte differentiation antigen gp100 are adoptively transferred into lympho-depleted mice bearing large, established, 14-day subcutaneous B16 melanoma (0.5-1 cm in diameter) on the day of treatment. Adoptive cell transfer in combination with interleukin interleukin-2 or interleukin-15 cytokine administration and vaccination using an altered form of the target antigen, gp100, can result in the complete and durable regression of large tumor burdens. Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans.

Original languageEnglish (US)
Pages (from-to)333-337
Number of pages5
JournalJournal of Leukocyte Biology
Volume76
Issue number2
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Immunotherapy
Adoptive Transfer
Animal Models
gp100 Melanoma Antigen
Interleukin-15
Neoplasms
Vitiligo
Experimental Melanomas
Interleukins
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
Tumor Burden
Autoimmunity
Interleukin-2
Vaccination
Therapeutics
Cytokines
T-Lymphocytes
Antigens

Keywords

  • Active immunization
  • Adoptive cell transfer
  • Cytokine
  • IFN-γ
  • Interleukin
  • Melanoma
  • MHC
  • Tumor
  • Vaccination

ASJC Scopus subject areas

  • Cell Biology

Cite this

Finkelstein, S. E., Heimann, D. M., Klebanoff, C. A., Antony, P. A., Gattinoni, L., Hinrichs, C. S., ... Restifo, N. P. (2004). Bedside to bench and back again: How animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology, 76(2), 333-337. https://doi.org/10.1189/jlb.0304120

Bedside to bench and back again : How animal models are guiding the development of new immunotherapies for cancer. / Finkelstein, Steven E.; Heimann, David M.; Klebanoff, Christopher A.; Antony, Paul A.; Gattinoni, Luca; Hinrichs, Christian S.; Hwang, Leroy N.; Palmer, Douglas C.; Spiess, Paul J.; Surman, Deborah R.; Wrzesiniski, Claudia; Yu, Zhiya; Rosenberg, Steven A.; Restifo, Nicholas P.

In: Journal of Leukocyte Biology, Vol. 76, No. 2, 08.2004, p. 333-337.

Research output: Contribution to journalArticle

Finkelstein, SE, Heimann, DM, Klebanoff, CA, Antony, PA, Gattinoni, L, Hinrichs, CS, Hwang, LN, Palmer, DC, Spiess, PJ, Surman, DR, Wrzesiniski, C, Yu, Z, Rosenberg, SA & Restifo, NP 2004, 'Bedside to bench and back again: How animal models are guiding the development of new immunotherapies for cancer', Journal of Leukocyte Biology, vol. 76, no. 2, pp. 333-337. https://doi.org/10.1189/jlb.0304120
Finkelstein, Steven E. ; Heimann, David M. ; Klebanoff, Christopher A. ; Antony, Paul A. ; Gattinoni, Luca ; Hinrichs, Christian S. ; Hwang, Leroy N. ; Palmer, Douglas C. ; Spiess, Paul J. ; Surman, Deborah R. ; Wrzesiniski, Claudia ; Yu, Zhiya ; Rosenberg, Steven A. ; Restifo, Nicholas P. / Bedside to bench and back again : How animal models are guiding the development of new immunotherapies for cancer. In: Journal of Leukocyte Biology. 2004 ; Vol. 76, No. 2. pp. 333-337.
@article{dfe7b43bbd8b494eb7f90470bf84d1e4,
title = "Bedside to bench and back again: How animal models are guiding the development of new immunotherapies for cancer",
abstract = "Immunotherapy using adoptive cell transfer is a promising approach that can result in the regression of bulky, invasive cancer in some patients. However, currently available therapies remain less successful than desired. To study the mechanisms of action and possible improvements in cell-transfer therapies, we use a murine model system with analogous components to the treatment of patients. T cell receptor transgenic CD8+ T cells (pmel-1) specifically recognizing the melanocyte differentiation antigen gp100 are adoptively transferred into lympho-depleted mice bearing large, established, 14-day subcutaneous B16 melanoma (0.5-1 cm in diameter) on the day of treatment. Adoptive cell transfer in combination with interleukin interleukin-2 or interleukin-15 cytokine administration and vaccination using an altered form of the target antigen, gp100, can result in the complete and durable regression of large tumor burdens. Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans.",
keywords = "Active immunization, Adoptive cell transfer, Cytokine, IFN-γ, Interleukin, Melanoma, MHC, Tumor, Vaccination",
author = "Finkelstein, {Steven E.} and Heimann, {David M.} and Klebanoff, {Christopher A.} and Antony, {Paul A.} and Luca Gattinoni and Hinrichs, {Christian S.} and Hwang, {Leroy N.} and Palmer, {Douglas C.} and Spiess, {Paul J.} and Surman, {Deborah R.} and Claudia Wrzesiniski and Zhiya Yu and Rosenberg, {Steven A.} and Restifo, {Nicholas P.}",
year = "2004",
month = "8",
doi = "10.1189/jlb.0304120",
language = "English (US)",
volume = "76",
pages = "333--337",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "2",

}

TY - JOUR

T1 - Bedside to bench and back again

T2 - How animal models are guiding the development of new immunotherapies for cancer

AU - Finkelstein, Steven E.

AU - Heimann, David M.

AU - Klebanoff, Christopher A.

AU - Antony, Paul A.

AU - Gattinoni, Luca

AU - Hinrichs, Christian S.

AU - Hwang, Leroy N.

AU - Palmer, Douglas C.

AU - Spiess, Paul J.

AU - Surman, Deborah R.

AU - Wrzesiniski, Claudia

AU - Yu, Zhiya

AU - Rosenberg, Steven A.

AU - Restifo, Nicholas P.

PY - 2004/8

Y1 - 2004/8

N2 - Immunotherapy using adoptive cell transfer is a promising approach that can result in the regression of bulky, invasive cancer in some patients. However, currently available therapies remain less successful than desired. To study the mechanisms of action and possible improvements in cell-transfer therapies, we use a murine model system with analogous components to the treatment of patients. T cell receptor transgenic CD8+ T cells (pmel-1) specifically recognizing the melanocyte differentiation antigen gp100 are adoptively transferred into lympho-depleted mice bearing large, established, 14-day subcutaneous B16 melanoma (0.5-1 cm in diameter) on the day of treatment. Adoptive cell transfer in combination with interleukin interleukin-2 or interleukin-15 cytokine administration and vaccination using an altered form of the target antigen, gp100, can result in the complete and durable regression of large tumor burdens. Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans.

AB - Immunotherapy using adoptive cell transfer is a promising approach that can result in the regression of bulky, invasive cancer in some patients. However, currently available therapies remain less successful than desired. To study the mechanisms of action and possible improvements in cell-transfer therapies, we use a murine model system with analogous components to the treatment of patients. T cell receptor transgenic CD8+ T cells (pmel-1) specifically recognizing the melanocyte differentiation antigen gp100 are adoptively transferred into lympho-depleted mice bearing large, established, 14-day subcutaneous B16 melanoma (0.5-1 cm in diameter) on the day of treatment. Adoptive cell transfer in combination with interleukin interleukin-2 or interleukin-15 cytokine administration and vaccination using an altered form of the target antigen, gp100, can result in the complete and durable regression of large tumor burdens. Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans.

KW - Active immunization

KW - Adoptive cell transfer

KW - Cytokine

KW - IFN-γ

KW - Interleukin

KW - Melanoma

KW - MHC

KW - Tumor

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=3442877804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442877804&partnerID=8YFLogxK

U2 - 10.1189/jlb.0304120

DO - 10.1189/jlb.0304120

M3 - Article

C2 - 15155774

AN - SCOPUS:3442877804

VL - 76

SP - 333

EP - 337

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 2

ER -